Showing results (281-290 of 346) with videos related to

Sort By:
Pageof 35
American Journal of Nephrology|December 15, 2017
Change in Hemoglobin Trajectory and Darbepoetin Dose Approaching End-Stage Renal Disease: Data from the Trial to Reduce Cardiovascular Events with Aranesp Therapy TrialFinnian R Mc Causland, Brian Claggett, Marc A Pfeffer, et al.
Radiology|July 31, 2002
Endovascular gamma irradiation of femoropopliteal de novo stenoses immediately after PTA: interim results of prospective randomized controlled trialKarsten Krueger, Peter Landwehr, Mark Bendel, et al.
Molecular Imaging and Biology|October 2, 2020
[18F]-JK-PSMA-7 PET/CT Under Androgen Deprivation Therapy in Advanced Prostate CancerFelix Dietlein, Peter Mueller, Carsten Kobe, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 23, 2006
The clinical relevance of stromal matrix metalloproteinase expression in ovarian cancerAparna A Kamat, Mavis Fletcher, Lynn M Gruman, et al.
Cancer Cell International|October 20, 2024
Curcumin attenuates smoking and drinking activated NF-κB/IL-6 inflammatory signaling axis in cervical cancerVivek K Kashyap, Prashanth K B Nagesh, Ajay K Singh, et al.
Cancer Immunology, Immunotherapy : CII|April 18, 2013
Vaccination with anti-idiotype antibody ganglidiomab mediates a GD(2)-specific anti-neuroblastoma immune responseHolger N Lode, Manuela Schmidt, Diana Seidel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 29, 2005
Preoperative serum tissue factor levels are an independent prognostic factor in patients with ovarian carcinomaLiz Y Han, Charles N Landen, Aparna A Kamat, et al.
European Journal of Heart Failure|May 15, 2026
Iron deficiency and risk of heart failure and cardiovascular events in CKD: Insights from the ASCEND-ND trialBrendon L Neuen, Henri Lu, Muthiah Vaduganathan, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|September 21, 2016
C-Reactive Protein and Risk of ESRD: Results From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)Finnian R Mc Causland, Brian Claggett, Emmanuel A Burdmann, et al.
Circulation|November 23, 2011
Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experienceHicham Skali, Hans-Henrik Parving, Patrick S Parfrey, et al.
Pageof 35